About
Pacegenix is a biotechnology company developing next-generation precision cardiology therapies, including a pipeline of first-in-class prodrugs targeting cardiac rhythm disorders and conditions such as hypertrophic cardiomyopathy. Founded in 2024 and incubated by Genesis BioCapital, the company focuses on translating precision medicine approaches into treatments for unmet cardiovascular needs.
Explore Pacegenix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.